ECSP13012621A - Heteroarilos y sus usos - Google Patents
Heteroarilos y sus usosInfo
- Publication number
- ECSP13012621A ECSP13012621A ECSP13012621A ECSP13012621A EC SP13012621 A ECSP13012621 A EC SP13012621A EC SP13012621 A ECSP13012621 A EC SP13012621A EC SP13012621 A ECSP13012621 A EC SP13012621A
- Authority
- EC
- Ecuador
- Prior art keywords
- heteroarilos
- compounds
- pi3k
- mtor
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
La presente invención proporciona compuestos de la fórmula I-A o I-B: en donde HY, G1, G2, R2, R12, W1, W2, n y el anillo A son como se describen en la memoria descriptiva. Los compuestos son inhibidores de PI3K y/o mTor y, así, son de utilidad para tratar trastornos proliferativos, inflamatorios o cardiovasculares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39251510P | 2010-10-13 | 2010-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13012621A true ECSP13012621A (es) | 2013-07-31 |
Family
ID=45938970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13012621 ECSP13012621A (es) | 2010-10-13 | 2013-05-13 | Heteroarilos y sus usos |
Country Status (23)
Country | Link |
---|---|
US (2) | US8765746B2 (es) |
EP (1) | EP2627181A4 (es) |
JP (1) | JP2013542941A (es) |
KR (1) | KR20140091462A (es) |
CN (1) | CN103237450A (es) |
AR (1) | AR083450A1 (es) |
AU (1) | AU2011316016A1 (es) |
BR (1) | BR112013009166A2 (es) |
CA (1) | CA2814688A1 (es) |
CL (1) | CL2013001009A1 (es) |
CO (1) | CO6801713A2 (es) |
CR (1) | CR20130204A (es) |
DO (1) | DOP2013000082A (es) |
EA (1) | EA201390539A1 (es) |
EC (1) | ECSP13012621A (es) |
IL (1) | IL225607A0 (es) |
MA (1) | MA34652B1 (es) |
MX (1) | MX2013004003A (es) |
PE (1) | PE20141044A1 (es) |
SG (1) | SG189396A1 (es) |
TW (1) | TW201307309A (es) |
UY (1) | UY33671A (es) |
WO (1) | WO2012051410A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
CA2750935A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
JP2013536193A (ja) | 2010-08-11 | 2013-09-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリール類およびその使用 |
CN103467481B (zh) * | 2012-06-07 | 2016-08-31 | 上海汇伦生命科技有限公司 | 二氢吡啶类化合物、其组合物、制备方法和用途 |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
MA43169B1 (fr) | 2015-11-06 | 2022-05-31 | Incyte Corp | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma |
TW201734003A (zh) | 2016-01-05 | 2017-10-01 | 英塞特公司 | 作為PI3K-γ抑制劑之吡啶及嘧啶化合物 |
US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
WO2019027368A1 (en) * | 2017-07-31 | 2019-02-07 | Agency For Science, Technology And Research | PROCESS FOR THE PREPARATION OF STAPLED PEPTIDES |
WO2019079469A1 (en) | 2017-10-18 | 2019-04-25 | Incyte Corporation | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA |
DK3847175T3 (da) | 2018-09-05 | 2024-03-18 | Incyte Corp | Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor |
CN110041349B (zh) * | 2019-05-15 | 2021-06-01 | 湖南科技大学 | 一种含螺二氢嘧啶衍生物及其制备方法和应用 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE581861A (es) | 1958-08-20 | |||
US3852293A (en) | 1972-06-21 | 1974-12-03 | Uniroyal Inc | 4-phenyl-2-(3-pyridyl)-thiazole carboxamides |
US3821384A (en) | 1972-10-06 | 1974-06-28 | Uniroyal Inc | Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same |
DE3021590A1 (de) | 1980-06-09 | 1981-12-17 | Hoechst Ag, 6000 Frankfurt | 4-halogen-5-(halogenmethyl-phenyl)-oxazol-derivate, ein verfahren zu ihrer herstellung und sie enthaltenden strahlungsempfindliche massen |
DD275870A1 (de) | 1988-09-27 | 1990-02-07 | Univ Leipzig | Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen |
PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
JP2001500482A (ja) | 1996-08-27 | 2001-01-16 | ノバルティス アクチェンゲゼルシャフト | 除草性s置換1,2,4,6―チアトリアジン類 |
JPH1087490A (ja) | 1996-09-10 | 1998-04-07 | Sagami Chem Res Center | インターロイキン6生産抑制剤、骨吸収抑制剤、抗骨粗鬆症剤、及びチアゾール化合物 |
PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
BR9804865B1 (pt) | 1997-04-24 | 2011-08-23 | pesticida 3-(fenil substituìdo)-5-(tienil ou furil)-1,2,4-triazóis, composição para controlar insetos ou ácaros, bem como processo para controlar insetos, ácaros, moscas brancas e afìdios, para proteger plantas de afìdios, ácaros ou insetos. | |
CA2336848A1 (en) | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
DE19858192A1 (de) | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Trifluormethyl-3-oxazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
MXPA02007134A (es) | 2000-01-18 | 2003-03-27 | Vertex Pharma | Inhibidores de girasa y usos de los mismos. |
DE60214701T2 (de) | 2001-04-13 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen |
ATE402164T1 (de) | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
US7405235B2 (en) | 2001-05-04 | 2008-07-29 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
DE60211348T2 (de) | 2001-08-13 | 2007-02-08 | Janssen Pharmaceutica N.V. | 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung |
ES2309207T3 (es) | 2001-09-05 | 2008-12-16 | Smithkline Beecham Plc | Derivados furanicos sustituidos con piridina como inhibidores de quinasa raf. |
US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
WO2003027100A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors |
CA2466284A1 (en) | 2001-11-08 | 2003-05-15 | Elan Pharmaceuticals, Inc. | N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
BR0313160A (pt) | 2002-08-08 | 2005-07-12 | Smithkline Beecham Corp | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto |
EP1534680B1 (en) | 2002-08-14 | 2012-02-22 | Pharmaco Investments, Inc. | Prenylation inhibitors and methods of their synthesis and use |
US20050004122A1 (en) | 2002-08-14 | 2005-01-06 | Brown Bradley B. | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
EP1708697A4 (en) | 2004-01-30 | 2007-11-28 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
JP2007531757A (ja) | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | 抗癌剤としての置換チオフェン誘導体 |
CN101031293A (zh) | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
CN101084194A (zh) | 2004-12-21 | 2007-12-05 | 默克公司 | 有丝分裂驱动蛋白抑制剂 |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
GB0503962D0 (en) | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
CN1834095B (zh) | 2005-03-18 | 2011-04-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
WO2006102194A1 (en) | 2005-03-21 | 2006-09-28 | Eli Lilly And Company | Imidazopyridazine compounds |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
GB0508471D0 (en) * | 2005-04-26 | 2005-06-01 | Celltech R&D Ltd | Therapeutic agents |
DE102005000046A1 (de) | 2005-04-28 | 2006-11-02 | Voith Patent Gmbh | Maschine zur Herstellung einer Faserstoffbahn |
CA2613517A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
CA2623327A1 (en) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
JP2007197324A (ja) | 2006-01-23 | 2007-08-09 | Toray Ind Inc | 2,4,5−置換−1,3−アゾール誘導体 |
CA2637933C (en) | 2006-01-24 | 2013-03-12 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
US7504513B2 (en) | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
EP2004623B1 (en) | 2006-03-27 | 2013-10-09 | Nerviano Medical Sciences S.r.l. | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
US7781433B2 (en) | 2006-04-26 | 2010-08-24 | Piramed Limited | Pharmaceutical compounds |
EP2016075A1 (en) | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Thiazole derivatives and their use as anti-tumour agents |
US8853244B2 (en) | 2006-05-23 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
WO2007138110A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
EP2035436B1 (en) * | 2006-06-26 | 2011-05-25 | UCB Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
US20080021026A1 (en) | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
WO2008014238A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
EP2385051A1 (en) | 2006-08-14 | 2011-11-09 | Schering Corporation | Process for making a substituted oxazole |
US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
KR101088196B1 (ko) | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | 티오펜 피라졸로피리미딘 화합물 |
EP2102199B1 (en) | 2006-12-04 | 2011-04-27 | AstraZeneca AB | Antibacterial polycyclic urea compounds |
WO2008083070A1 (en) | 2006-12-29 | 2008-07-10 | Neurogen Corporation | Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties |
GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
JP5461197B2 (ja) | 2007-02-02 | 2014-04-02 | ベイラー カレッジ オブ メディスン | 代謝障害を処置するための組成物および方法 |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
EP2114388B1 (en) | 2007-02-07 | 2015-05-20 | GlaxoSmithKline LLC | Inhibitors of akt activity |
BRPI0809867A2 (pt) | 2007-04-30 | 2014-09-30 | Genentech Inc | Composto, método de indução da apoptose em uma célula, método de sensibilização de uma célula para um sinal apoptótico, método para inibir a ligação de uma proteína iap a uma proteína caspase e métodos |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
WO2008157273A1 (en) | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
CA2699328A1 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
CN101932587A (zh) | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
GB0805818D0 (en) * | 2008-03-31 | 2008-04-30 | Ucb Pharma Sa | Therapeutic agents |
DK2276767T3 (da) | 2008-03-31 | 2014-07-14 | Genentech Inc | Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder |
ES2491522T3 (es) | 2008-06-19 | 2014-09-08 | Millennium Pharmaceuticals, Inc. | Derivados de tiofeno o tiazol y su uso como inhibidores de PI3K |
US20110160255A1 (en) | 2008-06-26 | 2011-06-30 | Rouse Meagan B | Inhibitors of akt activity |
GB0812309D0 (en) | 2008-07-03 | 2008-08-13 | Ucb Pharma Sa | Therapeutic agents |
US8420695B2 (en) | 2008-07-09 | 2013-04-16 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
US8673941B2 (en) | 2008-08-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of FAAH |
BRPI0921156A2 (pt) | 2008-11-11 | 2016-02-23 | Xcovery Holding Co Llc | inibidores de pi3k/mtor quinase |
GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
WO2010080873A1 (en) | 2009-01-08 | 2010-07-15 | Glaxo Group Limited | Oxazoles as modulators of chemokine receptors |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CA2750935A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
EP2430013B1 (en) | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
US20110021531A1 (en) | 2009-07-27 | 2011-01-27 | Chobanian Harry | Oxazole derivatives useful as inhibitors of faah |
JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
JP2013536193A (ja) | 2010-08-11 | 2013-09-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリール類およびその使用 |
WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
JP2015506347A (ja) | 2011-12-23 | 2015-03-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリールおよびその使用 |
-
2011
- 2011-10-13 WO PCT/US2011/056135 patent/WO2012051410A2/en active Application Filing
- 2011-10-13 AU AU2011316016A patent/AU2011316016A1/en not_active Abandoned
- 2011-10-13 EA EA201390539A patent/EA201390539A1/ru unknown
- 2011-10-13 TW TW100137181A patent/TW201307309A/zh unknown
- 2011-10-13 AR ARP110103813A patent/AR083450A1/es unknown
- 2011-10-13 EP EP11833402.8A patent/EP2627181A4/en not_active Withdrawn
- 2011-10-13 KR KR1020137012227A patent/KR20140091462A/ko not_active Application Discontinuation
- 2011-10-13 JP JP2013534002A patent/JP2013542941A/ja active Pending
- 2011-10-13 US US13/272,413 patent/US8765746B2/en active Active
- 2011-10-13 CA CA2814688A patent/CA2814688A1/en not_active Abandoned
- 2011-10-13 SG SG2013027958A patent/SG189396A1/en unknown
- 2011-10-13 BR BR112013009166A patent/BR112013009166A2/pt not_active IP Right Cessation
- 2011-10-13 MX MX2013004003A patent/MX2013004003A/es not_active Application Discontinuation
- 2011-10-13 PE PE2013000845A patent/PE20141044A1/es not_active Application Discontinuation
- 2011-10-13 UY UY0001033671A patent/UY33671A/es not_active Application Discontinuation
- 2011-10-13 CN CN2011800586347A patent/CN103237450A/zh active Pending
-
2013
- 2013-04-07 IL IL225607A patent/IL225607A0/en unknown
- 2013-04-12 CL CL2013001009A patent/CL2013001009A1/es unknown
- 2013-04-16 DO DO2013000082A patent/DOP2013000082A/es unknown
- 2013-05-06 MA MA35882A patent/MA34652B1/fr unknown
- 2013-05-08 CR CR20130204A patent/CR20130204A/es unknown
- 2013-05-10 CO CO13117641A patent/CO6801713A2/es not_active Application Discontinuation
- 2013-05-13 EC ECSP13012621 patent/ECSP13012621A/es unknown
-
2014
- 2014-06-27 US US14/318,223 patent/US20150148334A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20120214794A1 (en) | 2012-08-23 |
TW201307309A (zh) | 2013-02-16 |
WO2012051410A2 (en) | 2012-04-19 |
AU2011316016A1 (en) | 2013-05-30 |
MX2013004003A (es) | 2013-10-01 |
US8765746B2 (en) | 2014-07-01 |
CO6801713A2 (es) | 2013-11-29 |
BR112013009166A2 (pt) | 2016-07-26 |
UY33671A (es) | 2012-04-30 |
WO2012051410A3 (en) | 2012-07-26 |
EP2627181A4 (en) | 2014-03-19 |
CA2814688A1 (en) | 2012-04-19 |
CN103237450A (zh) | 2013-08-07 |
DOP2013000082A (es) | 2013-10-31 |
EA201390539A1 (ru) | 2013-09-30 |
PE20141044A1 (es) | 2014-09-07 |
KR20140091462A (ko) | 2014-07-21 |
CR20130204A (es) | 2013-09-03 |
MA34652B1 (fr) | 2013-11-02 |
EP2627181A2 (en) | 2013-08-21 |
US20150148334A1 (en) | 2015-05-28 |
AR083450A1 (es) | 2013-02-27 |
SG189396A1 (en) | 2013-05-31 |
JP2013542941A (ja) | 2013-11-28 |
IL225607A0 (en) | 2013-06-27 |
CL2013001009A1 (es) | 2013-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012621A (es) | Heteroarilos y sus usos | |
CR20130084A (es) | Heteroarilos y sus usos | |
CU24045B1 (es) | Aril piridinas como inhibidoras de sintasa de aldosterona | |
CO6771447A2 (es) | Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina | |
DOP2012000263A (es) | Compuestos quimicos | |
CR20120659A (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer | |
GT201400178A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
EA201690098A1 (ru) | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
CO6491087A2 (es) | Compuestos de urea que contienen heteroarilo 5,6 bicíclicos como inhibidores de quinasa | |
CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
BR112012016129A2 (pt) | composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer | |
EA201491305A1 (ru) | Конденсированные трициклические соединения в качестве ингибиторов raf киназы | |
UY34051A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
DOP2014000033A (es) | Aminoquinazolinas como inhibidores de quinasa | |
UY33888A (es) | Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas | |
EP2603216A4 (en) | HETEROARYLE AND USES THEREOF | |
CO6801724A2 (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
ECSP099827A (es) | Herbicidas novedosos | |
EA201690716A1 (ru) | ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ | |
CR20150148A (es) | Azaindolinas | |
CL2015000038A1 (es) | Métodos para preparar triazolopiridinas sustituidas y compuestos intermediarios. | |
EA201390620A1 (ru) | ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ | |
UY32303A (es) | Tiolactamas y sus usos | |
CL2011001850A1 (es) | Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. |